Sugi Predict

Sugi Predict / Compounds / SCHEMBL2406300

SCHEMBL2406300

SCHEMBL2406300

Nc1ncc(-c2cccc(F)c2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.54
▸ MAPT P10636 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ CSNK2A1 P68400 1/20 0.49
▸ HSD17B1 P14061 2/20 0.47
▸ HSD17B2 P37059 2/20 0.47
▸ TAAR1 Q96RJ0 1/20 0.46
▸ LOXL2 Q9Y4K0 1/20 0.43
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ PIM1 P11309 2/20 0.42
▸ PIM3 Q86V86 2/20 0.42
▸ PIM2 Q9P1W9 2/20 0.42
▸ MAP4K4 O95819 4/20 0.42
▸ HPGDS O60760 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29393032 1.00 KDM4E (0.54) KDM4EMAPTMEN1KMT2ANPC1
SCHEMBL12601168 0.82 MAP4K4 (0.53) KDM4EMAPTMEN1KMT2ANPC1
SCHEMBL14240524 0.82 ALDH1A1 (0.46) KDM4EMAPTMEN1KMT2ANPC1
SCHEMBL4831643 0.82 CSNK2A1 (0.59) MAPTNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL69900 0.81 CSNK2A1 (0.62) KDM4EMAPTNPC1ALDH1A1RAB9A
SCHEMBL40156 0.80 ADORA2A (0.49) MAPTNPC1ALDH1A1RAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL11145599 0.80 CSNK2A1 (0.61) KDM4EMAPTNPC1ALDH1A1RAB9A
Bromide SCHEMBL22834317 0.80 CSNK2A1 (0.61) KDM4EMAPTNPC1ALDH1A1RAB9A
SCHEMBL2406426 0.79 CSNK2A1 (0.49) MAPTNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL9954813 0.79 ALDH1A1 (0.54) MAPTMEN1KMT2ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 — — US disclosed
EP-3741757-B1 DIHYDROINDOLIZINONE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2023-07-26 — — EP disclosed
CN-111630052-B Dihydroindazinone derivatives 第一三共株式会社 2023-04-18 — — CN disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 — — US disclosed
US-11530211-B2 Dihydroindolizinone derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-12-20 — — US disclosed
US-20220339260-A1 METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES TOKYO INSTITUTE OF TECHNOLOGY (JP) 2022-10-27 — — US disclosed
US-11472798-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2022-10-18 — — US disclosed
EP-3998107-A1 METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES Tokyo Institute of Technology (JP) 2022-05-18 — — EP disclosed
CN-114040966-A Method for producing insulin-producing cell using dihydroindolizinone derivative 国立大学法人东京工业大学 2022-02-11 — — CN disclosed
US-20210053965-A1 DIHYDROINDOLIZINONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-02-25 — — US disclosed
EP-3741757-A1 DIHYDROINDOLIZINONE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2020-11-25 — — EP disclosed
CN-111630052-A Dihydroindazinone derivatives 第一三共株式会社 2020-09-04 — — CN disclosed
EP-2719696-A1 NOVEL KINASE INHIBITORS Asinex Limited (RU) 2014-04-16 — — EP disclosed
WO-2012169934-A1 NOVEL KINASE INHIBITORS ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "АСИНЭКС МЕДХИМ" (RU) 2012-12-13 — — WO disclosed
WO-2012085857-A1 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES ACTELION PHARMACEUTICALS LTD (CH) 2012-06-28 — — WO disclosed
WO-2012085852-A1 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES ACTELION PHARMACEUTICALS LTD (CH) 2012-06-28 — — WO disclosed
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 — — US disclosed
EP-1343503-B1 HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS SCHERING CORP (US) 2008-11-12 — — EP disclosed
US-7309704-B2 Heteroaryl urea neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION (US) 2007-12-18 — — US disclosed
US-7309704-B2 Heteroaryl urea neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION (US) 2007-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11472798-B2 Compounds UCHL1, UCHL3, UCHL5 KDM4E 175/4885MAPT 2227/4885MEN1 1789/4885
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 KDM4E 175/4885MAPT 2227/4885MEN1 1789/4885
US-11530211-B2 Dihydroindolizinone derivative INSR, GPR119, IAPP KDM4E 1470/4885MAPT 4042/4885MEN1 1938/4885
US-20220339260-A1 METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES IAPP, INSR, GPR119 KDM4E 1308/4885MAPT 3636/4885MEN1 2467/4885
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 KDM4E 452/4885MAPT 1419/4885MEN1 525/4885
US-20210053965-A1 DIHYDROINDOLIZINONE DERIVATIVE INSR, GPR119, IAPP KDM4E 1470/4885MAPT 4042/4885MEN1 1938/4885
US-20230052191-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 KDM4E 178/4885MAPT 2428/4885MEN1 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.